ivosidenib — United Healthcare
astrocytoma
Initial criteria
- Diagnosis of astrocytoma
- Disease is recurrent or progressive
- Presence of IDH1 mutation
- Disease is WHO grade 2, 3, or 4
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tibsovo therapy
Approval duration
12 months